The appropriate identification of bacterial infection is the basis for effective treatment and control of infective disease. Among this context, an emerging biomarker of infection is presepsin (PSP), recently described as early marker of different infections. PSP secretion has been shown to be associated with monocyte phagocytosis and plasmatic levels of PSP increase in response to bacterial infection and decrease after antibiotic treatment, therefore it can be considered a marker of activation of immune cell response towards an invading pathogen. Different methods have been developed to measure PSP and this review will briefly describe the different clinical fields of application of PSP, ranging from intensive care to neonatal infection, to orthopedic and pulmonary infection as well as fungal infections and cardiovascular infections.
Clinical application of presepsin as diagnostic biomarker of infection: overview and updates / E. Galliera, L. Massaccesi, E. de Vecchi, G. Banfi, M.M.C. Romanelli. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1437-4331. - 58:1(2020), pp. 11-17.
Clinical application of presepsin as diagnostic biomarker of infection: overview and updates
E. Galliera
Primo
;L. MassaccesiSecondo
;E. de Vecchi;M.M.C. RomanelliUltimo
2020
Abstract
The appropriate identification of bacterial infection is the basis for effective treatment and control of infective disease. Among this context, an emerging biomarker of infection is presepsin (PSP), recently described as early marker of different infections. PSP secretion has been shown to be associated with monocyte phagocytosis and plasmatic levels of PSP increase in response to bacterial infection and decrease after antibiotic treatment, therefore it can be considered a marker of activation of immune cell response towards an invading pathogen. Different methods have been developed to measure PSP and this review will briefly describe the different clinical fields of application of PSP, ranging from intensive care to neonatal infection, to orthopedic and pulmonary infection as well as fungal infections and cardiovascular infections.File | Dimensione | Formato | |
---|---|---|---|
10.1515_cclm-2019-0643.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
124.5 kB
Formato
Adobe PDF
|
124.5 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.